Omeros Corp
NASDAQ:OMER
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Omeros Corp
NASDAQ:OMER
|
US |
Omeros Corp
Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 213 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, immunologic diseases and cancers. The Company’s lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and coronavirus (COVID-19). OMS906, the Company’s inhibitor of MASP-3, the alternative pathway of complement, is in a Phase 1 clinical trial.
Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 213 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, immunologic diseases and cancers. The Company’s lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and coronavirus (COVID-19). OMS906, the Company’s inhibitor of MASP-3, the alternative pathway of complement, is in a Phase 1 clinical trial.
Turning point: Omeros said the fourth quarter of 2025 was a major inflection point, driven by the $240 million sale of zaltenibart to Novo Nordisk and FDA approval of YARTEMLEA for TA-TMA.
Launch traction: YARTEMLEA launched quickly, with first sales coming soon after January shipments, 24-hour delivery to patients, and early payer approval across all prior authorization requests.
Formulary progress: The company said YARTEMLEA has already reached formulary approval at 50% of the top 10 U.S. transplant centers and about 30% of the top 80.
Balance sheet: Omeros used Novo cash to pay off its $67.1 million term loan and $17.1 million of 2026 notes, leaving only $70.8 million of 2029 convertible notes.
Outlook: Management expects YARTEMLEA to be financially self-sustaining in 2026 and the company to reach positive cash flow in 2027.
Pipeline: Beyond YARTEMLEA, Omeros highlighted progress in OMS527, its T-CAT anti-infective platform, and OncotoX-AML, but these programs remain earlier stage.
